
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
The FDA has granted a Regenerative Medicine Advanced Therapy (RMAT) Designation to aglatimagene besadenovec (CAN-2409), an investigational off-the-shelf, replication-defective adenovirus for newly diagnosed intermediate- to high-risk localized prostate …